Merck COVID-19 pill linked to virus mutations – study (NYSE:MRK)
Summary by Ground News
Lagevrio, the FDA-authorized oral COVID-19 therapy, leads to new mutations in the virus, according to a new study. The researchers in the U.S. and U.K. collaborated with those in the Francis Crick Institute, Imperial College, and the University of Liverpool.